Increases to Poly Medicure Limited's (NSE:POLYMED) CEO Compensation Might Cool off for now
Key Insights
- Poly Medicure to hold its Annual General Meeting on 25th of September
- Salary of ₹64.2m is part of CEO Himanshu Baid's total remuneration
- Total compensation is 1,016% above industry average
- Poly Medicure's total shareholder return over the past three years was 132% while its EPS grew by 36% over the past three years
CEO Himanshu Baid has done a decent job of delivering relatively good performance at Poly Medicure Limited (NSE:POLYMED) recently. In light of this performance, CEO compensation will probably not be the main focus for shareholders as they go into the AGM on 25th of September. However, some shareholders will still be cautious of paying the CEO excessively.
See our latest analysis for Poly Medicure
How Does Total Compensation For Himanshu Baid Compare With Other Companies In The Industry?
Our data indicates that Poly Medicure Limited has a market capitalization of ₹209b, and total annual CEO compensation was reported as ₹214m for the year to March 2025. Notably, that's an increase of 25% over the year before. While this analysis focuses on total compensation, it's worth acknowledging that the salary portion is lower, valued at ₹64m.
For comparison, other companies in the India Medical Equipment industry with market capitalizations ranging between ₹88b and ₹282b had a median total CEO compensation of ₹19m. Hence, we can conclude that Himanshu Baid is remunerated higher than the industry median. Furthermore, Himanshu Baid directly owns ₹24b worth of shares in the company, implying that they are deeply invested in the company's success.
| Component | 2025 | 2024 | Proportion (2025) |
| Salary | ₹64m | ₹58m | 30% |
| Other | ₹150m | ₹114m | 70% |
| Total Compensation | ₹214m | ₹172m | 100% |
Talking in terms of the industry, salary represents all of total compensation among the companies we analyzed, while other remuneration is, interestingly, completely ignored. Poly Medicure sets aside a smaller share of compensation for salary, in comparison to the overall industry. If total compensation is slanted towards non-salary benefits, it indicates that CEO pay is linked to company performance.
A Look at Poly Medicure Limited's Growth Numbers
Over the past three years, Poly Medicure Limited has seen its earnings per share (EPS) grow by 36% per year. It achieved revenue growth of 17% over the last year.
Shareholders would be glad to know that the company has improved itself over the last few years. It's also good to see decent revenue growth in the last year, suggesting the business is healthy and growing. Looking ahead, you might want to check this free visual report on analyst forecasts for the company's future earnings..
Has Poly Medicure Limited Been A Good Investment?
Boasting a total shareholder return of 132% over three years, Poly Medicure Limited has done well by shareholders. As a result, some may believe the CEO should be paid more than is normal for companies of similar size.
In Summary...
Given that the company's overall performance has been reasonable, the CEO remuneration policy might not be shareholders' central point of focus in the upcoming AGM. However, if the board proposes to increase the compensation, some shareholders might have questions given that the CEO is already being paid higher than the industry.
CEO compensation is one thing, but it is also interesting to check if the CEO is buying or selling Poly Medicure (free visualization of insider trades).
Of course, you might find a fantastic investment by looking at a different set of stocks. So take a peek at this free list of interesting companies.
Valuation is complex, but we're here to simplify it.
Discover if Poly Medicure might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.